Maximum Dose of Vyvanse
The maximum recommended daily dose of Vyvanse (lisdexamfetamine) is 70 mg once daily for both ADHD and binge eating disorder in patients with normal renal function. 1
Standard Dosing
The FDA-approved maximum dose is clearly established at 70 mg/day for:
- ADHD in adults and pediatric patients ≥6 years old 1
- Moderate to severe binge eating disorder in adults 1
This represents the ceiling dose regardless of indication, with dosing typically starting at 30 mg once daily and titrated in 10-20 mg increments at approximately weekly intervals until reaching the maximum of 70 mg 1.
Dose Adjustments for Renal Impairment
Critical caveat: The maximum dose must be reduced in patients with kidney disease 1:
- Severe renal impairment (GFR 15 to <30 mL/min/1.73 m²): Maximum 50 mg/day
- End-stage renal disease (GFR <15 mL/min/1.73 m²): Maximum 30 mg/day
International Guideline Concordance
Asian ADHD guidelines from 2024 confirm the 70 mg maximum dose for lisdexamfetamine (LDX) in Japan, which aligns with FDA recommendations 2. This consistency across regulatory bodies reinforces that 70 mg represents the evidence-based upper limit.
Clinical Context
The 70 mg ceiling was established through dose-ranging studies demonstrating efficacy across the 30-70 mg range, with the highest dose (70 mg) showing numerically superior effects in pediatric ADHD trials 3. Research has confirmed effectiveness and tolerability at this maximum dose in both short-term (12 weeks) and long-term (up to 12 months) studies 4, 5.
Important: Unlike older stimulant guidelines that sometimes mentioned exceeding PDR limits in rare cases 6, the FDA label for Vyvanse provides no such flexibility—70 mg is the absolute maximum for patients with normal renal function, and exceeding this dose is not supported by evidence or regulatory approval.